Janssens P J, Wagener D J, Nagengast F M, Hoogenraad W J, Wobbes T, Joosten H J, Oei S B, van der Steen-Banasik E M
Division of Medical Oncology, University Hospital Nijmegen, The Netherlands.
Anticancer Res. 1993 Jan-Feb;13(1):209-14.
The results of treatment in 74 patients treated in 1978-1990 for adenocarcinoma of the esophagus were retrospectively analyzed. The overall five-year survival was 7.8%, the median survival 10.0 months. Eighteen patients underwent a resection, in 13 patients with curative and in 5 patients with palliative intent. The median survival for these groups was 13.5 and 5.8 months, respectively. Thirty-one patients were irradiated. The response rate according to the WHO passage score was 79%. The median duration of response and survival was 6.0 and 9.5 months, respectively. Twenty patients were given palliative treatment, in the form of an endoprosthesis (10 patients), an endoprosthesis with chemotherapy (4 patients) or only chemotherapy (6 patients). The median duration of survival of patients in the palliative group was 6.5 months. The data are discussed in relation to results of treatment described in the literature.
回顾性分析了1978年至1990年期间接受治疗的74例食管腺癌患者的治疗结果。总体五年生存率为7.8%，中位生存期为10.0个月。18例患者接受了手术切除，其中13例为根治性手术，5例为姑息性手术。这些组的中位生存期分别为13.5个月和5.8个月。31例患者接受了放疗。根据世界卫生组织的通路评分，缓解率为79%。缓解和生存的中位持续时间分别为6.0个月和9.5个月。20例患者接受了姑息治疗，形式为内置假体（10例患者）、内置假体联合化疗（4例患者）或仅化疗（6例患者）。姑息治疗组患者的中位生存期为6.5个月。结合文献中描述的治疗结果对这些数据进行了讨论。
